Cost a concern as China commits to inactivated polio vaccines
This article was originally published in Scrip
In an effort to respond to the World Health Organization's call for a polio-free world, China has decided to shift to the use of safer injected, inactivated polio vaccines (IPVs) by 2018, marking a step away from the current oral polio vaccine (OPV), which has been widely administered in the country since the 1960's due to its low cost and high efficacy.
You may also be interested in...
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
The China Food and Drug Administration has released the final version of its biosimilars guideline1.